Sensorion: FDA designation for SENS-401.

(CercleFinance.com) - Sensorion has announced that the FDA has designated the status of orphan drug to SENS-401, a molecule being developed for the treatment of hearing disorders, in the prevention of ototoxicity induced by platinum in pediatrics.


The company said that platinum-based chemotherapeutic agents, including cisplatin, induce hearing loss severe in 50%-60% of patients, and that there is currently no treatment available for this condition.

The SENS-401 is also being developed in the treatment of acute hearing loss. Sensorion plans to start Phase 2 clinical trials in this indication in the US and Europe in the first half of 2018.


Copyright (c) 2017 CercleFinance.com. All rights reserved.